Casdin Capital LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Casdin Capital LLC
CRD #169579
SEC #801-110894
CIK #0001730779, 0001534262, 0001534261
AUM 2,872.6 M (2026-03-31)
Employees 29 (38% Investors, 0% Brokers)
Fees
Minimum
Phone212-897-5430
Address1350 Avenue of The Americas
New York, NY 10019
Source [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn]
Total AUM ($B)
6.04.83.62.41.20.02010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Item 5:           Fees and Compensation

This brochure is delivered to qualified purchasers and therefore does not contain our advisory service fee
schedule. The fees applicable to our client funds are set forth in detail in their respective governing
documents and each fund’s private placement memorandum together with the relevant supplements
thereto, which set forth the relevant asset-based and performance-based fee percentages applicable to
investors. We only offer interest in our client funds to investors that qualify as accredited investors and
qualified purchasers as defined in the Investment Company Act of 1940, as amended.

As compensation for our services to our client funds, the Firm, or an affiliate of the Firm, typically
receives, as set forth in the respective private placement memorandum and/or the relevant supplement
thereto, at a fund level, a management fee based on a percentage of assets we manage and a
performance-based fee (i.e., a “performance allocation” or “carried interest”) based on capital
appreciation.

For the Hedge Funds, the management fee is generally calculated based on the aggregate capital account
balances of applicable investors in a fund; however, the management fee will be calculated based on
the lesser of historical cost or the estimated fair market value for certain non-marketable or illiquid
investments in the Hedge Funds (“Special Situation Investments” as further described in Casdin
Partners’ and Casdin Offshore’s private placement memorandum). Management fees are calculated and
payable quarterly in advance. Management fees are deducted directly from our client funds’ investors’
accounts.

For PE Funds, the management fee is generally calculated based on the invested capital attributable to
applicable investors, as determined under the applicable fund governing documents. Management fees are
calculated and payable quarterly in advance. Management fees are generally payable out of amounts
otherwise distributable to investors and, as applicable, through drawdowns of commitments, and are
reflected in the applicable investors’ capital accounts.

For investors in the Hedge Funds, we typically structure our performance allocation as a debit against
the capital accounts of the limited partners of a fund and a credit to the capital account of the General
Partner. The performance allocation is subject to a loss carryforward requirement or “high water mark”
(i.e., we only receive a performance allocation when an investor’s account value for the year has
recovered any losses from prior years, reduced proportionately by any withdrawals or redemptions an
investor makes). Each client fund’s net profits are calculated net of the management fee, but before the
performance allocation. Net profits include unrealized appreciation or depreciation of marketable
positions, as well as any dividends or distributions. The Master Fund’s investors do not pay a
performance allocation on any unrealized appreciation on Special Situation Investments but may pay a
performance allocation upon the realization of profits related to such Special Situation Investments.
Certain investors who hold a particular class or tranche that is no longer offered in Casdin Partners and
Casdin Offshore respectively, are subject to a “hurdle rate” equal to the 12-month trailing average for five-
year U.S. Treasury Bills issued prior to the last day of the relevant performance period. The performance
allocation is applied only to net profits of a particular limited partner or shareholder for the year in
excess of the “hurdle rate.” The “hurdle rate” is capped at 3% per annum.

Investors in the PE Funds will pay carried interest based on realized profits. The carried interest will
generally occur after an investor in the PE Funds has received a return of all of its capital contributions.

We waive the portion of the management fee and incentive allocation or carried interest that is allocable
to investors who are Casdin affiliates, Casdin employees, members of their immediate family and their
lineal descendants, trusts or other entities established for their benefit and family or other foundations
established by such persons. Our fees are generally non-negotiable, but in the General Partner’s sole
discretion, the management fee and performance allocation may be waived, reduced or calculated
differently with respect to certain investors in our client funds.

Casdin Capital, LLC                                                                   Form ADV Part 2A

Each of our client funds bear various costs, fees and expenses in addition to the compensation payable to
the Firm or an affiliate of the Firm. Although we set forth enumerated lists below, all investors in our
client funds and prospective investors should review the private placement memorandum of their
respective fund (including any relevant supplements) and other governing documents for each applicable
client, which may discuss additional costs, fees and expenses not discussed below.

Our client funds, and consequently the investors in our client funds, generally incur the following
expenses:

     •   offering, organizational and reorganizational expenses (including legal and accounting fees,
         printing costs, travel, “blue sky” filing fees and expenses and out-of-pocket expenses)

     •   expenses related to the research, due diligence and monitoring of actual and prospective
         investments (whether or not consummated) and the consummation of investments,
         including, without limitation, (i) third-party investment sourcing fees; (ii) fees and expenses
         related to obtaining research and market data (including, without limitation, travel, lodging,
         meal expense, any information technology hardware, software or other technology
         incorporated into the cost of obtaining such research and market data); (iii) due diligence
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7:            Types of Clients

Each of our client funds is a pooled investment vehicle, or more specifically, a private investment fund,
the securities of which are offered to certain qualified investors on a private placement basis. Any initial
and additional subscription minimums are disclosed in such client fund’s governing documents. The Firm,
however, is not precluded from advising types of client funds that are not listed above.

Investment advice is provided directly to such pooled investment vehicles and not individually to the
investors. Investors in such pooled investment vehicles may include, but are not limited to, high net
worth individuals, family offices, fund of hedge funds, endowments, foundations, trusts, charitable
organizations, insurance companies, pension plans, sovereign wealth funds and corporate or business

Casdin Capital, LLC                                                                        Form ADV Part 2A

entities.

This brochure is not an offer to invest in any of our client funds.
Sector Form 13F Holdings Value ($B)
Revolution Medicines Inc 0.3
CM Life Sciences Inc 0.2
Relay Therapeutics Inc 0.1
Biolife Solutions Inc 0.1
Fluidigm Corp 0.1
Illumina Inc 0.1
Structure Therapeutics Inc 0.1
10X Genomics Inc 0.0
Denali Therapeutics Inc 0.0
Beam Therapeutics Inc 0.0
View All
Holdings by Sector ($B)
5.04.03.02.01.00.02014201820222027
Type Form D Funds Date Sold AUM
HF Casdin Amplify Fund LP 2022-11-22 0.2 M
HF Casdin Partners FO1 - MSV LP 2022-11-22 24.6 M
PE Casdin Private Growth Equity Fund II LP [2022-02-16] 233.6 M 363.1 M
Filed 2021-11-01 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE Casdin Private Growth Equity Fund LP [2021-02-25] 179.4 M 227.5 M
Filed 2020-11-09 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
VC Casdin Venture Opportunities Fund LP [2018-03-28] 30.0 M 42.7 M
Filed 2018-03-01 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
HF Casdin Partners Master Fund LP [2013-11-20] 1,178.3 M 2,239.1 M
Filed 2026-03-13 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 7 2.9
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 7 2.9
By Discretionary
Discretionary 7 2.9
Non-Discretionary 0 0.0
Total 7 2.9
By Non-United States Persons
Non-United States Persons 2.2
United States Persons 0.6
Total 7 2.9
Form D Directors Role # Filings # Firms 2011 - 2026
Ronan Guilfoyle Director 358 108
Eli Casdin Director, Executive Officer 18 2
Andrew Malik Director 6 2
Casdin Capital LLC Promoter 5 2
Casdin Private Growth Equity Fund GP LLC Executive Officer 1 1
Casdin Private Growth Equity Fund II GP LLC Executive Officer 1 1
Casdin Venture Opportunities Fund GP LLC Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001534261]
3 [0001534261]
4 [0001534261]
SC 13D [0001534261]
SC 13G [0001534261]
D [0001534262]
3 [0001730779]
4 [0001730779]
D [0001730779]
Form 13D/13G Filer Form 13D/13G Subject Filed
Casdin Capital LLC Biolife Solutions Inc [2026-06-04]
Casdin Capital LLC Century Therapeutics Inc [2024-11-27]
Casdin Capital LLC Neurogene Inc [2024-11-08]
Casdin Capital LLC Codexis Inc [2024-09-26]
Casdin Capital LLC Century Therapeutics Inc [2024-04-18]
Casdin Capital LLC Relay Therapeutics Inc [2023-10-02]
Casdin Capital LLC Standard Biotools Inc [2022-04-08]
Casdin Capital LLC Tango Therapeutics Inc [2021-08-19]
Casdin Capital LLC Tenaya Therapeutics Inc [2021-08-09]
Casdin Capital LLC Maxcyte Inc [2021-08-03]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI5493007Q67HVCQ3CVZ14
Form 3/4/5 Subject 2011 - 2026
Casdin Eli
GeneDx Holdings Corp
Casdin Partners Master Fund LP
Casdin Capital LLC
Casdin Partners GP LLC
Biolife Solutions Inc
Casdin Private Growth Equity Fund LP
Casdin Private Growth Equity Fund GP LLC
Casdin Private Growth Equity Fund II GP LLC
Standard Biotools Inc
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-12-04 Buy 150,000 $1.45 217,500
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-12-03 Buy 75,000 $1.44 108,000
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-12-02 Buy 125,000 $1.42 177,500
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-25 Buy 7,550,000 $1.30 9,815,000
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-24 Buy 150,000 $1.43 214,500
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-20 Buy 450,000 $1.30 585,000
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-19 Buy 350,000 $1.28 448,000
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-18 Buy 275,000 $1.23 338,250
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-17 Buy 225,000 $1.22 274,500
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-14 Buy 250,000 $1.24 310,000
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-13 Buy 450,000 $1.20 540,000
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-12 Buy 375,000 $1.19 446,250
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-11 Buy 300,000 $1.20 360,000
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-10 Buy 275,000 $1.17 321,750
Standard Biotools Inc LAB
Common Stock, $0.001 par value per share
2025-11-07 Buy 225,000 $1.12 252,000
Biolife Solutions Inc BLFS
Common Stock, par value $0.001 per share
2025-10-15 Sell 750,000 $28.55 21,412,500
Standard Biotools Inc LAB
Common Stock
2025-08-15 Buy 150,000 $1.22 183,000
Standard Biotools Inc LAB
Common Stock
2025-08-14 Buy 133,220 $1.21 161,196
Standard Biotools Inc LAB
Common Stock
2025-08-13 Buy 75,000 $1.31 98,250
Biolife Solutions Inc BLFS
Common Stock, par value $0.001 per share
2025-08-11 Sell 500,000 $22.60 11,300,000
showing 20 of 135 most recent transactions
Comparable Firms State AUM
Marblegate Asset Management LLC
CT 2,923.8 M
Polychain Capital LP
CA 2,901.3 M
RRG Capital Management LLC
CA 2,893.8 M
Keywise Capital Management HK Limited
2,886.4 M
Man Investment Partners US LP
NY 2,879.3 M
Electric Capital Partners LLC
CA 2,877.3 M
Quantitative Systematic Strategies LLC
FL 2,834.0 M
Pamplona Capital Management LLC
NY 2,828.8 M
Two SEAS Capital LP
NY 2,821.4 M
Newmarket Investment Management LP
PA 2,820.3 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com